Methotrexate plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib‐randomized phase II study Commence

BACKGROUND: Methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) has limited progression‐free survival (PFS) benefit. We hypothesized that adding cetuximab to methotrexate improves PFS. METHODS: In the phase‐Ib‐study, patients with R/M SCCHN received met...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Head Neck
Autors principals: Ham, Janneke C., van Meerten, Esther, Fiets, W. Edward, Beerepoot, Laurens V., Jeurissen, Frank J. F., Slingerland, Marije, Jonker, Marianne A., Husson, Olga, van der Graaf, Winette T. A., van Herpen, Carla M. L.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7216894/
https://ncbi.nlm.nih.gov/pubmed/31903657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.26053
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars